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Abstract
Over the past few years, new-generation cell-based assays have demonstrated a robust association of autoantibodies to
full-length human myelin oligodendrocyte glycoprotein (MOG-IgG) with (mostly recurrent) optic neuritis, myelitis and
brainstem encephalitis, as well as with acute disseminated encephalomyelitis (ADEM)-like presentations. Most experts now
consider MOG-IgG-associated encephalomyelitis (MOG-EM) a disease entity in its own right, immunopathogenetically
distinct from both classic multiple sclerosis (MS) and aquaporin-4 (AQP4)-IgG-positive neuromyelitis optica
spectrum disorders (NMOSD). Owing to a substantial overlap in clinicoradiological presentation, MOG-EM was often
unwittingly misdiagnosed as MS in the past. Accordingly, increasing numbers of patients with suspected or established
MS are currently being tested for MOG-IgG. However, screening of large unselected cohorts for rare biomarkers can
significantly reduce the positive predictive value of a test. To lessen the hazard of overdiagnosing MOG-EM, which may
lead to inappropriate treatment, more selective criteria for MOG-IgG testing are urgently needed. In this paper, we
propose indications for MOG-IgG testing based on expert consensus. In addition, we give a list of conditions atypical
for MOG-EM (“red flags”) that should prompt physicians to challenge a positive MOG-IgG test result. Finally, we provide
recommendations regarding assay methodology, specimen sampling and data interpretation.
Keywords: Myelin oligodendrocyte glycoprotein (MOG) antibodies, Consensus recommendations, Diagnosis, Antibody
testing, Multiple sclerosis (MS), Neuromyelitis optica spectrum disorders (NMOSD), Optic neuritis (ON), Myelitis
Background
Over the past few years, the role of immunoglobulin G
serum antibodies to myelin oligodendrocyte glycoprotein
(MOG-IgG) in patients with inflammatory CNS demyelin-
ation has been revisited. While antibodies to MOG were
originally thought to be involved in multiple sclerosis (MS),
based on results from enzyme-linked immunosorbent
assays employing linearized or denatured MOG peptides as
antigen, more recent studies using new-generation cell-
based assays have demonstrated a robust association of
antibodies to full-length, conformationally intact human
MOG protein with (mostly recurrent) optic neuritis (ON),
myelitis and brainstem encephalitis, as well as with acute
disseminated encephalomyelitis (ADEM)-like presentations,
rather than with classic MS [1–11].
Based on evidence from (a) immunological studies
suggesting a direct pathogenic impact of MOG-IgG, (b)
neuropathological studies demonstrating discrete histo-
pathological features, (c) serological studies reporting a
lack of aquaporin-4 (AQP4)-IgG in almost all MOG-
IgG-positive patients, and (d) cohort studies suggesting
differences in clinical and paraclinical presentation,
treatment response and prognosis, MOG-IgG is now
considered to denote a disease entity in its own right,
distinct from classic MS and from AQP4-IgG-positive
neuromyelitis optica spectrum disorders (NMOSD), which
is now often referred to as MOG-IgG-associated enceph-
alomyelitis (MOG-EM) [11–13].
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Importantly, however, MOG-EM and MS show a rele-
vant phenotypic, i.e., clinical as well as radiological,
overlap [3, 14]: like MS, MOG-EM follows a relapsing
course in most cases [3, 6], at least in adults, and 33 and
15% of adult patients with MOG-EM meet McDonald’s
and Barkhof ’s criteria for MS, respectively, at least once
over the course of disease [3, 14]. Accordingly, many
patients with MOG-EM were falsely classified as having
MS in the past [3, 4]. However, such misclassification has
potential therapeutic implications: (a) similar to what
has been observed in AQP4-IgG-positive NMOSD, some
drugs approved for MS might be ineffective or even harmful
in MOG-EM owing to differences in immunopathogenesis
[3, 4, 15–17]; (b) MOG-EM is associated with a high risk of
flare-ups after cessation of steroid treatment for acute
attacks and may thus require close monitoring and
careful steroid tapering [3, 18–22]; and (c) patients
positive for MOG-IgG might be particularly responsive to
antibody-depleting treatments for acute attacks such as
plasma exchange or immunoadsorption [3, 4, 9, 14, 23, 24],
to B cell-targeted long-term therapies such as rituximab,
to treatment with intravenous immunoglobulins (IVIG)
(especially in children [25]), and to immunosuppressive
treatments [3, 6, 14, 25, 26]. Therefore, increasing numbers
of patients with suspected or established MS are currently
being screened for MOG-IgG.
However, screening of large unselected populations for
rare biomarkers generally decreases the positive predictive
value of diagnostic tests by increasing the rate of false-
positive results [27, 28]. Even if assays with high specificity
(≥99%) are used, true-positive (TP) results can easily be
outnumbered by false-positive (FP) results if the preva-
lence of a marker is low and the number of samples tested
is high. This also applies to MOG-IgG testing. Based on a
hypothetical prevalence of 1% genuinely MOG-IgG-
positive cases among all patients currently diagnosed with
MS, testing of 100,000 patients with an almost flawless,
99% specific and 100% sensitive assay would result in an
unacceptable ratio of 990 FP results to 1000 TP results.
Therefore, unselected screening of all patients with sus-
pected or established MS for MOG-IgG should be dis-
couraged and more specific criteria for MOG-IgG testing
are urgently needed.
In this paper, we propose for the first time indications for
MOG-IgG testing based on expert consensus. In addition,
we give a list of conditions considered atypical for MOG-
EM (“red flags”) that should prompt physicians to challenge
the validity of a positive MOG-IgG test result. Finally,
we provide recommendations regarding assay methodology,
specimen sampling, and data interpretation.
Methods
PubMed was searched for articles published between
February 2007 and February 2017 using the following
search term: (“myelin oligodendrocyte glycoprotein”
OR MOG) AND (antibody OR antibodies OR IgG). All
articles identified by this means were reviewed by a
core group of physicians (S.J., B.W., F.P., K.R.) for clin-
ical and paraclinical findings that have been frequently re-
ported in association with MOG-IgG seropositivity in
patients with CNS demyelination and which, therefore,
may justify MOG-IgG testing, as well as for potential “red
flags”, i.e., conditions that are typically found in inflamma-
tory disorders of the CNS but have been reported to be
absent or very rare in MOG-IgG-positive patients and
thus may indicate diagnoses other than MOG-EM. Based
on core group consensus, a first set of recommendations
was formulated and then circulated to a broader panel of
experts in the field from Australia, Denmark, France,
Germany, Italy, Japan, South Korea, Spain, UK, and the
USA for discussion and refinement. Panel members were
invited by the core group based on eminence and previous
contributions to the field. Based on several rounds of
core group-led peer-to-peer discussions of the individual
recommendations with all individual members of the panel,
a final set of evidence- as well as eminence-based recom-
mendations was drawn up to which all members gave their
approval. All recommendations given here should be con-
sidered as expert consensus.
Recommendations on MOG-IgG testing
In Table 1, we propose indications for MOG-IgG testing
based on clinical and paraclinical findings that are
typical of MOG-EM and/or atypical for MS and were
considered by the panel members to be associated with
pre-test odds high enough to justify MOG-IgG testing
or that demand MOG-IgG testing because of potentially
significant therapeutic consequences of a positive test
result according to expert consensus. These recommen-
dations apply to all patients with suspected CNS demye-
lination of putative autoimmune etiology and an either
monophasic or relapsing disease course. Given the very
low pre-test probability [29], we recommend against
general MOG-IgG testing in patients with a progressive
disease course. In Table 2, we give a number of case
vignettes of patients considered to be at high risk of
MOG-EM to illustrate the broad spectrum of symptoms
associated with that syndrome and the practical feasibil-
ity and relevance of the proposed criteria. In Table 3, we
give a number of recommendations regarding assay se-
lection, specimen sampling, and data interpretation.
Finally, Table 4 lists conditions (“red flags”) that we be-
lieve are atypical for MOG-EM and should thus prompt
physicians to challenge a positive MOG-IgG test result
and seek a better explanation for the patients’ clinical
and paraclinical findings.
In practice, many patients diagnosed with AQP4-IgG-
negative NMOSD according to the IPND 2015 criteria
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Table 1 Recommended indications for MOG-IgG testing in patients presenting with acute CNS demyelination of putative autoimmune
etiology
1. Monophasic or relapsing acute optic neuritis, myelitis, brainstem encephalitis, encephalitis, or any combination thereof,
and
2. radiological or, only in patients with a history of optic neuritis, electrophysiological (VEP) findings compatible with CNS demyelination,
and
3. at least one of the following findings:
MRI
a. Longitudinally extensive spinal cord lesion (≥3 VS, contiguous) on MRI (so-called LETM)a,b
b. Longitudinally extensive spinal cord atrophy (≥3 VS, contiguous) on MRI in patients with a history compatible with acute myelitisa
c. Conus medullaris lesions, especially if present at onsetc
d. Longitudinally extensive optic nerve lesion (e.g., >1/2 of the length of the pre-chiasmal optic nerve, T2 or T1/Gd)d
e. Perioptic Gd enhancement during acute ONe
f. Normal supratentorial MRI in patients with acute ON, myelitis and/or brainstem encephalitis
g. Brain MRI abnormal but no lesion adjacent to a lateral ventricle that is ovoid/round or associated with an inferior temporal lobe
lesion and no Dawson’s finger-type or juxtacortical U fiber lesion (Matthews-Jurynczyk criteriaf)
h. Large, confluent T2 brain lesions suggestive of ADEM
Fundoscopy
i. Prominent papilledema/papillitis/optic disc swelling during acute ON
CSF
j. Neutrophilic CSF pleocytosisg or CSF WCC > 50/μlh
k. No CSF-restricted OCB as detected by IEF at first or any follow-up examinationi (applies to continental European patients only)
Histopathology
l. Primary demyelination with intralesional complement and IgG deposits
m. Previous diagnosis of “pattern II MS” j
Clinical findings
n. Simultaneous bilateral acute ON
o. Unusually high ON frequency or disease mainly characterized by recurrent ON
p. Particularly severe visual deficit/blindness in one or both eyes during or after acute ON
q. Particularly severe or frequent episodes of acute myelitis or brainstem encephalitis
r. Permanent sphincter and/or erectile disorder after myelitis
s. Patients diagnosed with “ADEM”, “recurrent ADEM”, “multiphasic ADEM” or “ADEM-ON”
t. Acute respiratory insufficiency, disturbance of consciousness, behavioral changes, or epileptic seizures (radiological signs of
demyelination required)
u. Disease started within 4 days to ~ 4 weeks after vaccination
v. Otherwise unexplained intractable nausea and vomiting or intractable hiccups (compatible with area postrema syndrome)a
w. Co-existing teratoma or NMDAR encephalitis (low evidencek)
Treatment response
x. Frequent flare-ups after IVMP, or steroid-dependent symptomsl (including CRION)
y. Clear increase in relapse rate following treatment with IFN-beta or natalizumab in patients diagnosed with MS (low evidence)
Note that these recommendations are primarily intended for use in adults and adolescents. Indications for MOG-IgG testing in young children need not to be as rigorous
as in adults, since MOG-EM is thought to be significantly more frequent among young children with acquired demyelinating disease (up to 70%; frequency declining
with age) than among their adult counterparts (≤ 1% in Western countries; probably ≤ 5% in Japan and other Asian countries because of lower MS prevalence), which
reduces the risks attached to antibody screening outlined in the Introduction
Abbreviations: ADEM acute disseminated encephalomyelitis, ADEM-ON ADEM with recurrent ON, AQP4 aquaporin-4, CNS central nervous system, CRION chronic relapsing
inflammatory optic neuropathy, CSF cerebrospinal fluid, EM encephalomyelitis, Gd gadolinium, IA immunoadsorption, IgG immunoglobulin G, IVMP intravenous
methylprednisolone, LE left eye, LETM longitudinally extensive transverse myelitis, MOG myelin oligodendrocyte glycoprotein, MRI magnetic resonance imaging, MS mul-
tiple sclerosis, NMDAR N-methyl-D-aspartate receptor, NMO neuromyelitis optica, OCB oligoclonal IgG bands, ON optic neuritis, PEX plasma exchange, RE right
eye, RRMS relapsing-remitting MS, VEP visual evoked potentials, VS vertebral segments, WCC white cell count
aIf costs play a role and disease is stable: test AQP4-IgG first, since more frequent in that condition than MOG-IgG. If disease is active, requiring fast decision-making, or
if costs play no role: test AQP4-IgG and MOG-IgG in parallel
bLETM is common both in MOG-EM and in AQP4-NMOSD, but rarely if ever occurs in MS; as a caveat, however, non-contiguous lesions may mimic LETM in some
patients with MS. N.B.: Short lesions do not per se exclude MOG-EM. MRI shows short lesions at least once over the disease course in around 44–52% of all
MOG-EM patients [3, 39] and around 15% of all AQP4-NMOSD patients [40]. Lesion length may also depend on MRI timing issues, with shorter lesions detected
when the MRI was performed early in the evolution of acute myelitis or in clinical remission. Both axial and sagittal plane images should be used to judge le-
sion extent. LETM has also been shown to be frequently present at disease onset in MOG-IgG-positive children with manifestations other than isolated ON
(32/40 or 80% of all examined cases) [41]
cPresent in 6/8 patients in [7] (at onset); 4/6 in [8]; 4/11 in [35]; 3/12 in [42]; 5/26 (not all had lumbar MRI) in [3]; and in 13/40 pediatric patients (at onset) with
manifestations other than isolated ON [41]
dRamanathan et al. (2015) reported a median optic nerve lesion length of 23.1 mm (IQR 18-33) in MOG-IgG-related ON (N=19); this compares to a median lesion
length of 9.9 mm (IQR 6.6-19.8; N=13) in MS-related ON observed in the same study [43] and of 10.5 mm in a second, independent study (N=26) [44]. Recent data
suggest that also involvement (T2, T1/Gd or optic nerve swelling) of > 6/12 optic nerve segments (anterior orbital RE/LE, posterior orbital RE/LE, canalicular RE/LE,
intracranial RE/LE, chiasm right/left half, optic tract right/left side) may be associated with increased pre-test odds for MOG-IgG (observed in 6/19 [32%] MOG-IgG-
positive ON patients but in none of 13 [0%] MS-ON patients) [43]. Longitudinal extensive lesions involving at least 4 of 5 segments (anterior intraorbital segment,
posterior intraorbital segment, canalicular, intracranial, chiasmal) were also noted in >=50% of MOG-IgG-positive patients in [45]. By contrast, lesions in MS-related
ON extended only over 1 (70%) or 2 (30%) of 9 segments (intraorbital RE/LE, canalicular RE/LE, intracranial RE/LE, chiasmal, optic tract right/left side) in [44], and a
mean extension of just 2.2/10 segments (orbital RE/LE, canalicular RE/LE, intracranial RE/LE, chiasma right/left half, optic tract right/left side) was observed in MS-
ON in [46]. Longitudinal extensive lesions ranging over more than the half of the distance between the optic nerve head and the chiasm were also reported in 3/
3 patients in [47] and in 6/10 (60%) in [3]. Finally, 9/10 MOG-ON Han patients (90%) showed involvement of all three segments of the pre-chiasmal optic nerve
(intraorbital, canalicular, intracranial) in [48], in 6 of whom chiasmal and/or optic tract involvement was noted in addition
eObserved in 11/28 patients during acute ON in [3], in 6/18 in [49], and in 6/8 in [48], but not usually in MS. Perioptic T2 hyperintensity alone does not count
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[30] will meet also the criteria for MOG-IgG testing
given in Table 1 and should thus be tested. However,
MOG-IgG testing should not be restricted to patients
with AQP4-IgG-negative NMOSD. While this approach
seems to offer simplicity, it would be inappropriate for
several reasons: (1) The IPND criteria for AQP4-IgG-
negative NMOSD demand dissemination in space, which
would prevent testing of many patients with syndromes
compatible with MOG-EM (e.g., patients with isolated
longitudinally extensive transverse myelitis [LETM], iso-
lated bilateral ON, or isolated brainstem encephalitis).
(2) They include magnetic resonance imaging (MRI)
criteria that are based on lesion distribution patterns
observed in AQP4-IgG-positive NMOSD, some of which
reflect areas of high AQP4 expression; however, AQP4 is
not the target antigen in MOG-EM. Accordingly, lesion
distribution may differ between NMOSD and MOG-
EM and some MOG-EM patients do not satisfy
these criteria (e.g., patients with recurrent bilateral
non-longitudinal ON without chiasm involvement plus
non-NMOSD-typical brain lesions, those with severe and
recurrent non-longitudinally extensive myelitis, and those
with ADEM-like presentation with severe brain and
brainstem involvement but no area postrema lesion).
(3) Such a recommendation would imply testing of all
patients for AQP4-IgG before they were tested for
MOG-IgG, which might unnecessarily delay diagnosis
and treatment. (4) The criteria for AQP4-IgG-negative
NMOSD require exclusion of other diagnoses; this
would constitute a logical repugnancy, since a
Table 2 Case vignettes of patients at risk of MOG-IgG seropositivity (examples)
Example 1: 35-year-old woman presenting with bilateral acute ON. Develops transient blindness; fundoscopy shows papilledema; lumbar puncture
reveals lymphomonocytic pleocytosis with 10% neutrophils and negative OCBs; brain MRI shows perioptic Gd enhancement but is otherwise
normal; flaring up of symptoms after tapering of oral steroids; later recurrent ON attacks, stabilization with rituximab.
Example 2: 40-year-old woman with two attacks of acute, OCB-negative myelitis. Spine MRI shows an isolated short spinal cord lesion at first attack and
a longitudinally extensive spinal cord lesion at relapse; brain MRI abnormal but no Dawson’s finger-type lesion, no juxtacortical U fibre lesion, and no
lesion adjacent to a lateral ventricle that is ovoid or associated with an inferior temporal lobe lesion [36, 37, 50]; flaring up of myelitis symptoms
after discontinuation of intravenous steroid treatment, good response to PEX.
Example 3: Young man with a previous diagnosis of “OCB-negative RRMS”. Predominantly ON and myelitis attacks; conus lesion with severe
erectile and sphincter disturbance after first myelitis; longitudinally extensive optic nerve lesion with involvement of the optic chiasm; increase in
relapse rate under treatment with interferon-beta but stabilization with rituximab.
Example 4: 42-year-old woman presenting with incomplete, painful tetraparesis. Previous diagnosis of RRMS with positive OCB; spinal cord MRI re-
veals a contiguous lesion extending from C3 to T1; negative serology for AQP4-IgG.
Example 5: ADEM-like presentation with large white matter lesions and disturbance of consciousness, brainstem lesions, and involvement of the
entire spinal cord in a 25-year-old woman; onset 3 weeks after vaccination.
Example 6: Simultaneous unilateral ON and LETM extending into the brainstem in a 39-year-old man. CSF pleocytosis (90 white cells/μl) with 5%
neutrophils; no CSF-restricted OCB; negative AQP4-IgG serostatus.
Example 7: Young woman presenting with recurrent and steroid-dependent isolated ON, previously classified as CRION; normal brain MRI.
Example 8: Young man with acute encephalitis and seizures. MRI reveals large cortical/subcortical white matter lesions not involving the inferior
temporal lobe; good response to steroids; negative for typical viral and autoimmune causes of encephalitis.
Abbreviations: ADEM acute disseminated encephalomyelitis, AQP4 aquaporin-4, CRION chronic relapsing inflammatory optic neuropathy, CSF cerebrospinal fluid,
EM encephalomyelitis, Gd gadolinium, IgG immunoglobulin G, LETM longitudinally extensive transverse myelitis, MOG myelin oligodendrocyte glycoprotein,
MRI magnetic resonance tomography, MS multiple sclerosis, ON optic neuritis, RRMS relapsing-remitting MS
fPositive in ≥ 90% of RRMS patients [37, 36, 50]. By contrast, ovoid/round lesions adjacent to a lateral ventricle, lesions adjacent to a lateral ventricle in association with a
temporal lobe lesion, and Dawson’s finger-type lesions were absent in 21/21 (100%) MOG-IgG-positive patients in a mixed adult (n = 15) and pediatric (n = 6) cohort [36,
37] and juxtacortical U fiber lesions in 20/21 (95.2%). Recently, a lack of Dawson’s finger-type lesions in MOG-IgG-positive patients has been confirmed in an exclusively
pediatric cohort (absent in 68/69 [98.6%]; the only patient positive for Dawson’s finger lesions had typical MS and was negative for MOG-IgG at re-testing); U fiber lesions
were absent in 65/69 (94.2%) MOG-IgG-positive pediatric patients in the same study [41]
gPresent at least once in 64% of patients with pleocytosis [3] (median 22% of all white cells; range 3–69%) but typically absent in MS. N.B.: Neutrophilic
pleocytosis is also frequently found in AQP4-IgG-positive NMOSD [51]
hObserved in 43% (14/36) of MOG-IgG-positive patients with pleocytosis (peak values) [3], but only rarely in patients with MS (≤ 2% according to [52]; 1/71 patient
≥ 15 years of age [range 15–29] in [53])
iOligoclonal bands (OCB) have been reported in up to 98% of patients with MS in central and Northern Europe [53] but only in around 12–13% of patients with
MOG-EM in two recent Central European studies [3, 54]; of note, many MOG-EM patients previously falsely diagnosed with MS were atypical in that they had no
OCB in a recent multicenter study [3]. As a caveat, it should be noted that positive OCB do NOT exclude MOG-EM [3] and that the frequency of OCB in MS may be lower
in Asian patients (e.g., 40–80% in Japan) as well as in some regions in Europe such as Sardinia (84% in a recent study [55]), possibly depending on genetic factors. “No
CSF-restricted OCB” refers to the presence of OCB patterns 1 (no OCB), 4 (mirror pattern without additional IgG bands present exclusively in the CSF), or 5 (monoclonal
IgG band present both in the CSF and in the serum) [56]
jSome patients diagnosed with “pattern II MS” lesions, which are characterized by IgG and complement deposits, were shown by independent groups to have in
fact MOG-EM, suggesting that the current histopathological criteria may not be sufficiently specific to distinguish between MS and MOG-EM [24, 57, 58]
kPatients with teratoma and positive MOG-IgG serostatus have been identified in two cohorts so far (2/74; 3%) [3, 4, 59]; expression of CNPase, an oligodendrocyte marker,
has been described in mature teratomas, and oligodendrogliomas may arise in mature teratomas. Additional testing for NMDAR antibodies is highly recommended in
patients with teratoma and neurological symptoms [60]. Recent, though preliminary, reports suggest that MOG-EM and NMDAR encephalitis may occasionally co-exist [61]
lRe-occurrence of symptoms after tapering of oral steroids [3, 18, 20, 22, 62]
Table 1 (Continued)
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negative test for MOG-IgG would be a prerequisite
for MOG-IgG testing. (5) Finally, but less importantly,
using NMOSD criteria for diagnosing MOG-EM
would, in addition to resulting in a substantial loss in
sensitivity and specificity, also be confusing to non-
experts, given that AQP4-IgG-positive NMOSD and
MOG-EM are distinct diseases with different target
antigens (AQP4 vs. MOG), pathophysiology (astrocy-
topathy vs. primary demyelination), and clinical
spectra.
Alternatively, should we restrict MOG-IgG testing to
patients with AQP4-IgG-negative NMO according to
Wingerchuk’s 2006 criteria [31]? This would again result
in a substantial loss of patients at high risk of MOG-
EM, since those criteria require a history of both ON
and myelitis and would thus be inappropriate. Of note,
MOG-IgG testing in patients with seronegative NMO
according to the 2006 criteria is already covered by our
recommendation to test all patients with LETM for
MOG-IgG (see Table 1), since the 2006 criteria strictly
require a history of LETM in patients negative for
AQP4-IgG.
Instead, we propose to base the indication for
MOG-IgG testing in patients with suspected CNS
demyelination on the presence of specific clinical
and paraclinical findings that are considered typical
for MOG-EM and/or atypical for conventional MS
(see Table 1).
During the consensus-finding process, concerns
were raised regarding inclusion of the following
treatment-related indications for MOG-IgG testing in
Table 1:
Table 3 Recommendations on methodology, test parameters, specimen sampling and data interpretation
Assay types
Cell-based assays (IFT/FACS): Recommended (current gold standard); must employ full-length human MOG as target antigen; use of Fc-specific (or IgG1-
specific [63]) secondary antibodies highly recommended to avoid cross-reactivity with (specifically or non-specifically co-binding) IgM and IgA antibodies
[11, 63]
Immunohistochemistry: Currently not recommended (less sensitive than cell-based assays, limited data available on specificity [11, 64], sensitivity
depends on tissue donor species [64]); if used, Fc-specific secondary antibodies adsorbed against tissue donor IgG required in order to avoid
cross-reactivity with IgM and IgA or with tissue-bound donor IgG
Peptide-based ELISA, Western blot: Insufficiently specific, obsolete
Biomaterial
Serum: Recommended (specimen of choice); shipment at 4 °C or on dry ice advisable if samples do no arrive within 1–2 days
Cerebrospinal fluid: Not usually required, since MOG-IgG is produced mostly extrathecally, resulting in lower CSF than serum titers [2]; potentially
helpful in rare, selected cases (e.g., strong background due to co-existing high-titer non-MOG serum antibodies); shipment at 4 °C or on dry ice
advisable
Immunoglobulin classes
Testing for MOG-IgG: Recommended
Testing for MOG-IgM and/or MOG-IgA: Currently not recommended; additional MOG-IgM and MOG-IgA antibodies have been described in some
MOG-IgG-positive patients [1, 2]; the clinical relevance of isolated MOG-IgM or -IgA results is unknown; testing for antibodies of the IgM class
requires removal of total IgG from the sample to avoid both false-negative (due to high-affinity IgG displacing IgM) and false-positive (due to
IgM anti-IgGFc rheumatoid factors) results [65]
Data reporting
Immunoglobulin class detected, assay type, antigenic substrate and biomaterial used, titer/concentration/units, assay-specific cut-offs and performing
laboratory should all be documented (e.g., “Serum MOG-IgG 1:1280 [cut-off ≥ 1:160a; assay: live CBA, Innsbruck lab; antigen: full-length human
MOG]”)
Data interpretation
As with all laboratory tests, positive test results should always be interpreted in the context of the patient’s overall presentation; if “red flags” as
defined in Table 4 are present, re-testing of the positive serum sample (or, if not anymore available, at least testing of a follow-up serum sample) is
recommended; to reduce the potential risk of reproducing false-positive results due to issues inherent to the very method employed, use of a
second (and, in the case of discrepant results, third) methodologically different cell-based assay is advisable; if in doubt, seek expert advice from
a specialized center
Timing issues
MOG-IgG serum concentrations depend on disease activity (with higher median concentrations during acute attacks than during remission) and
treatment status (with lower concentrations while on immunosuppression) and may transiently vanish after plasma exchange [3]; if MOG-IgG is
negative but MOG-EM still suspected, re-testing during acute attacks, during treatment-free intervals, or 1–3 months after plasma exchange (or
IVIGb) is recommended – N.B.: Some cases of monophasic MOG-positive EM/ADEM in adult patients have been described in which MOG-IgG
disappeared permanently following clinical recovery [2–4, 33–35]
Abbreviations: ADEM acute disseminated EM, CBA cell-based assay, CSF cerebrospinal fluid, ELISA enzyme-linked immunosorbent assay, EM encephalomyelitis, FACS
fluorescence-activated cell sorting, IgG/A/M immunoglobulin G/A/M, IFT indirect fluorescence test, IVIG intravenous immunoglobulins, MOG myelin oligodendrocyte
glycoprotein, PEX plasma exchange
aNote that the cut-off given here is an example only; actual cut-off values are assay-dependent.
bGenerally, pretreatment with IVIG is liable to cause false negative and false positive results in antibody assays [66–68]; whether any of the tests currently used for
detecting MOG-IgG are affected by IVIG pretreatment has not been investigated so far.
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a. Particularly good response to antibody-depleting
therapies (plasma exchange [PEX],
immunoadsorption [IA])
b. Particularly good response to B cell-depleting
therapies (rituximab, ocrelizumab, ofatumumab) but
relapse immediately after re-occurrence of B cells
It was argued by some members of the panel that
good responses to PEX, IA, or B cell depletion have
also been observed in conventional MS. However,
consensus was achieved that if present in addition to
any of the indications listed in Table 1, good re-
sponse to antibody or B cell-depleting treatments or
IVIG further increases the pre-test likelihood of
MOG-EM and thus supports the decision to test for
MOG-IgG.
Taking into account that MOG-IgG serum concentra-
tions depend on disease activity (with higher concentra-
tions during acute attacks) and treatment status (with
lower concentrations while on immunosuppression) as
well as on assay sensitivity, we recommend re-testing
patients during acute attacks or during treatment-free
intervals and/or in a second cell-based assay if MOG-
IgG was negative at first examination but MOG-EM
is still suspected based on the list of indications given
in Table 1 [3].
Only sparse data are available on the usefulness of regu-
lar monitoring of antibody titers in individual patients
known to be positive for MOG-IgG. Median MOG-IgG
titers have indeed been shown to be significantly higher
during relapse than during remission [2], making regular
MOG-IgG testing a potentially promising method for
predicting attacks and monitoring treatment efficacy. How-
ever, there are several limitations: While titers > 1:2560
were found only during acute attacks in a recent study
using a live cell-based assay [2], some patients still had rela-
tively low titers during acute attacks and others had rela-
tively high titers during remission, suggesting that
additional factors such as blood–CSF barrier damage, T cell
activation, antibody affinity, or complement-activating ac-
tivity may be involved, with no general cut-off value for re-
lapse induction [2]. In addition, treatment effects could
Table 4 “Red flags”: conditions that should prompt physicians to challenge a positive test result (consider re-testing the patient, ideally using
an alternative, i.e., methodologically different cell-based assay; in case of doubt, consider seeking expert advice from a specialized center)
Disease course
Chronic progressive disease (very rare in MOG-IgG-positive patients [3]), including SPMS (especially SPMS without relapses) and PPMSa
Sudden onset of symptoms, e.g., < 4 h from onset to maximum (consider ischemic cause), or continuous worsening of symptoms over weeks
(consider tumor, sarcoidosis, etc.)
MRI
Lesion adjacent to a lateral ventricle that is ovoid/round or associated with an inferior temporal lobe lesion, or Dawson’s finger-type lesion
Active brain MRI over time with silent increase in lesion burden between relapses (limited evidence)
CSF
Bi- or trispecific MRZ reactionb (consider MS)
Serology
MOG-IgG levels at or just barely above the assay-specific cut-offc, especially (but not exclusively) if clinical picture is atypical
Positive MOG-IgM and/or MOG-IgA result with negative MOG-IgG (clinical significance unknown)
MOG-IgG positivity in the CSF but not in the serumd (MOG-IgG is typically produced extrathecally)
AQP4-IgG/MOG-IgG “double-positive” test results (extremely rare; should prompt retesting for both antibodies)e
Others
Clinical or paraclinical findings suggesting diagnoses other than MOG-EM, NMOSD or MS (e.g., neurotuberculosis, neuroborreliosis, neurosyphilis,
neurosarcoidosis, Behçet syndrome, subacute combined degeneration of the spinal cord, Leber’s hereditary optic neuropathy, vasculitis, CNS lymphoma,
gliomatosis cerebri, paraneoplastic neurological disordersf, PRES, PML, and evidence for CNS infectiong)
Combined central and peripheral demyelination [69] (MOG is not expressed in the peripheral nervous system)h
Abbreviations: AQP4 aquaporin-4, CNS central nervous system, CSF cerebrospinal fluid, EM encephalomyelitis, Ig immunoglobulin, MOG myelin oligodendrocyte
glycoprotein, MRZ measles, rubella and zoster virus, MS multiple sclerosis, NMDAR N-methyl-D-aspartate receptor, NMOSD neuromyelitis optica spectrum disorder,
PPMS primary progressive MS, PML progressive multifocal leukoencephalopathy, PRES posterior reversible encephalopathy syndrome, SPMS secondary progressive
MS, WCC white cell count
aJust one borderline MOG-IgG result found among 290 patients with PPMS (n = 174) or SPMS (n = 116) in a recent study [29]
bMeasles (M), rubella (R), and zoster (Z) reaction: Intrathecal synthesis against at least two of these three viral agents (i.e., against M + R, M + Z, R + Z, or M + R + Z);
part of the polyspecific, intrathecal humoral immune reaction in MS; present in around 70% of MS patients but not at all, or only very rarely, in MOG- or AQP4-
IgG-positive patients (MOG-EM: 0/11; NMO: 1/42; “ADEM”: 1/26) [3, 70, 71]
cExcept in patients who were previously positive at levels clearly above the cut-off, in which case low-titer results may reflect true (spontaneous or treatment-
related) decline in antibody levels
dMay be valid in the rare instances in which co-existing serum autoantibodies hamper serum analysis but not CSF analysis (false-negative serum test)
eIf confirmed in a second assay and IPND criteria for NMOSD are met, co-existence of MOG-EM and AQP4-NMOSD must be assumed
fNote, however, that preliminary reports suggest occasional co-incidence of MOG-EM and NMDAR encephalitis [61]; in such patients teratoma needs to be
excluded [60]
gNote that CSF findings in MOG-EM (as well as in AQP4-NMOSD) may mimic CNS infection with neutrophil pleocytosis, impaired blood-CSF barrier function, and a
lack of CSF-restricted oligoclonal bands [3, 40, 51]. White cell counts in MOG-EM ranged between 6 and 306 cells/μl (median 33; quartile range 13–125) in a recent
European study [2]; WCC ≥ 100 cells/μl were present at least once in 9/32 (28.1%) patients; neutrophil granulocytes were present at least once in 9/14 (64.3%) patients
with pleocytosis and available data (median 22% of all white cells; range 3–69%)
hMay be true positive in the rare cases in which MOG-EM and unrelated peripheral neuropathy of other cause co-exist
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play a role. Finally, intervals sufficient to detect imminent
attacks in time have not yet been defined. Based on
experience from studies on AQP4-IgG-positive NMOSD,
in which serum antibody levels rise only very shortly before
an attack [32], very close testing intervals may be required,
which would make monitoring both expensive and challen-
ging from a practical point of view. Accordingly, no general
recommendation for regular monitoring of MOG-IgG ti-
ters for relapse prediction or treatment monitoring can
currently be made.
Of note, some patients have been reported in whom
MOG-IgG disappeared over time [2, 33–35]. Interestingly,
many of these patients had monophasic disease. By con-
trast, MOG-IgG was detectable at the last follow-up in all
patients (n = 18) with a relapsing disease course and avail-
able follow-up samples (mean interval 33 months since
first testing; maximum follow-up period 10 years) in a
recent study [2]. Disappearance of MOG-IgG after the
initial attack might thus have prognostic implications, and
re-testing of MOG-IgG-positive patients 6–12 months
after the first attack might therefore be useful. However,
there are some limitations: Most of the reported mono-
phasic patients were children or juveniles, and most had
ADEM. Moreover, no long-term data were provided for
most cases. This is important, since titers may fall below
cut-off temporarily following treatment with steroids,
plasma exchange, or immunosuppressants (or even spon-
taneously) and rise again at a later disease stage; accord-
ingly, (transient) seroconversion has also been observed in
a few patients with relapsing disease [2, 14, 33]. It would
therefore be challenging to base long-term treatment deci-
sions solely on whether MOG-IgG disappears or not after a
first attack. If long-term treatment with immunosuppres-
sants or oral steroids is abandoned by reason of conversion
to seronegativity, close monitoring of the patient’s MOG-
IgG serostatus is highly recommended to confirm seronega-
tivity in the long-term course. Before making a diagnosis of
“monophasic” MOG-EM and thus a decision against long-
term treatment, one should also take into account that the
interval between first and second attack in relapsing MOG-
EM varies considerably among patients, with the second
clinical attack occurring only after an interval of several
years in some cases [3].
Diagnostic criteria for MOG-EM
There is an unmet need for diagnostic criteria for MOG-
EM. However, no specific clinical or radiological findings
(except for the general requirement of a demyelinating
CNS lesion) have yet been identified that are present in
all MOG-IgG-positive patients and which would thus
represent a diagnostic sine qua non. A lack of Dawson’s
finger lesions and ovoid/round lesions on brain MRI
have been proposed to be typical for MOG-EM, but this
awaits confirmation in independent and larger cohorts
[36, 37]. We propose that for the time being MOG-EM
should be diagnosed in all patients who meet all of the
following criteria:
1. Monophasic or relapsing acute ON, myelitis,
brainstem encephalitis, or encephalitis, or any
combination of these syndromes
2. MRI or electrophysiological (visual evoked
potentials in patients with isolated ON) findings
compatible with CNS demyelination
3. Seropositivity for MOG-IgG as detected by means
of a cell-based assay employing full-length human
MOG as target antigen
In patients with conditions considered “red flags” as
defined in Table 4 and in whom MOG-IgG has not yet
been confirmed in a second (and third if necessary),
methodologically different cell-based assay, a diagnosis
of “possible MOG-EM” should be made, especially in
the context of clinical studies and treatment trials.
Limitations and caveats
It is a limitation that all recommendations given here are
necessarily based on expert consensus, owing to a lack of
systematic and prospective studies. Moreover, as a general
caveat, it should be stressed that before a diagnosis of
MOG-EM is made, all available information, including
clinical, radiological, electrophysiological, and laboratory
data, need to be taken into account, and differential diag-
noses, some of which are listed in Table 4, need to be ex-
cluded. Most of the information given in a previous
consensus paper on differential diagnosis in MS [38] is
also pertinent to MOG-EM. Finally, while the criteria pro-
posed here can certainly help in identifying pediatric pa-
tients at high risk of being positive for MOG-IgG, they are
primarily intended for use in adults and adolescents. Indi-
cations for MOG-IgG testing in children do not need to
be as rigorous as in adults, since MOG-IgG is thought to
be much more common in children with acquired demye-
linating disease (up to 70% depending on age) than in
their adult counterparts (≤ 1% in Western countries; prob-
ably ≤ 5% in Japan and other Asian countries because of
lower MS prevalence). In consequence, the risk of an un-
favorable ratio of FP to TP results outlined above is lower
in children. While ADEM is the predominant clinical as-
sociation in young children, in older children with MOG
antibodies there is a shift towards presentation with ON,
myelitis, and/or brainstem symptoms [11].
Conclusion
Here, we give for the first time indications for MOG-IgG
testing and propose preliminary criteria for the diag-
nosis of MOG-EM. While we believe that our recom-
mendations are highly timely considering the large
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numbers of patients currently being tested, we are
well aware that they reflect current knowledge in an
evolving field and may need to be adjusted when new
clinical and paraclinical data emerge and novel and
optimized assays become available.
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